In 2003, there seemed to be good reasons to leave weight-loss drugs out of the benefit, write Inmaculada Hernandez of the University of California, San Diego, and coauthors in their September 2023 editorial in the Journal of General Internal Medicine, Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform. When members of Congress worked on the Part D benefit, the drugs available on the market were known to have limited effectiveness and unpleasant side effects
Semaglutide has been studied for weight management, type 2 diabetes, and cardiovascular risk reduction in certain patients
Without funding, public health will be decimated even more and we will lack preparedness for our state
Elevated levels of FSH and LH are associated with male infertility
Under NICE Technology Appraisal 875, Wegovy is recommended for use within specialist weight management services for a maximum of 2 years on the NHS
Ipamorelin: release-side signal via the ghrelin receptor (GHSR1a)